• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticancer drug R&D of gastrointestinal cancer in China: Current landscape and challenges.

作者信息

Shen Lin

机构信息

Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.

出版信息

Innovation (Camb). 2022 Apr 18;3(3):100249. doi: 10.1016/j.xinn.2022.100249. eCollection 2022 May 10.

DOI:10.1016/j.xinn.2022.100249
PMID:35535132
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9077517/
Abstract
摘要

相似文献

1
Anticancer drug R&D of gastrointestinal cancer in China: Current landscape and challenges.中国胃肠道癌抗癌药物研发：现状与挑战
Innovation (Camb). 2022 Apr 18;3(3):100249. doi: 10.1016/j.xinn.2022.100249. eCollection 2022 May 10.
2
Evolution of drug regulations and regulatory innovation for anticancer drugs in China.中国抗癌药物法规的演变与监管创新
Acta Pharm Sin B. 2022 Dec;12(12):4365-4377. doi: 10.1016/j.apsb.2022.08.004. Epub 2022 Aug 13.
3
Anticancer drug R&D landscape in China.中国抗癌药物研发概况
J Hematol Oncol. 2020 May 13;13(1):51. doi: 10.1186/s13045-020-00877-3.
4
Advances on anticancer new drugs in China and the USA in 2020: from ongoing trial to drug approval.2020年中美两国抗癌新药进展：从临床试验到药物获批
J Natl Cancer Cent. 2021 Aug 22;1(4):147-152. doi: 10.1016/j.jncc.2021.08.002. eCollection 2021 Dec.
5
Challenges in anticancer drug R&D in China.中国抗癌药物研发面临的挑战。
Lancet Oncol. 2019 Feb;20(2):183-186. doi: 10.1016/S1470-2045(18)30865-9.
6
The current status of the biosimilars landscape in China.中国生物类似药领域的现状。
Biologicals. 2024 Feb;85:101744. doi: 10.1016/j.biologicals.2024.101744. Epub 2024 Feb 24.
7
The landscape of cancer research and cancer care in China.中国癌症研究与癌症护理的现状
Nat Med. 2023 Dec;29(12):3022-3032. doi: 10.1038/s41591-023-02655-3. Epub 2023 Dec 12.
8
Research and development of mAb drugs in China: a look from policy perspectives.中国单抗药物的研发：政策视角的观察。
Hum Vaccin Immunother. 2019;15(11):2695-2705. doi: 10.1080/21645515.2019.1605809. Epub 2019 May 22.
9
Analysis of Incentive Policies and Initiatives on Orphan Drug Development in China: Challenges, Reforms and Implications.中国孤儿药开发的激励政策和举措分析：挑战、改革与启示
Orphanet J Rare Dis. 2023 Jul 27;18(1):220. doi: 10.1186/s13023-023-02684-8.
10
Characteristics of clinical trials of new oncology drugs approved in China.中国批准的新型肿瘤药物临床试验特点。
Cancer. 2024 Mar 1;130(5):671-682. doi: 10.1002/cncr.35106. Epub 2023 Nov 20.

引用本文的文献

1
Risk of cardiovascular disease among cancer survivors: systematic review and meta-analysis.癌症幸存者患心血管疾病的风险：系统评价与荟萃分析。
EClinicalMedicine. 2025 Jun 5;84:103274. doi: 10.1016/j.eclinm.2025.103274. eCollection 2025 Jun.
2
Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights.2023 - 2024年获批的全球首创药物：突破与见解。
Innovation (Camb). 2025 Jan 14;6(4):100801. doi: 10.1016/j.xinn.2025.100801. eCollection 2025 Apr 7.
3
Development and validation of a nomogram for obesity and related factors to detect gastric precancerous lesions in the Chinese population: a retrospective cohort study.中国人群中用于检测胃癌前病变的肥胖及相关因素列线图的开发与验证：一项回顾性队列研究
Front Oncol. 2024 Nov 20;14:1419845. doi: 10.3389/fonc.2024.1419845. eCollection 2024.
4
The NEDD4/FLRT2 axis regulates NSCLC cell stemness.NEDD4/FLRT2轴调节非小细胞肺癌细胞的干性。
Front Pharmacol. 2024 Oct 9;15:1459978. doi: 10.3389/fphar.2024.1459978. eCollection 2024.
5
Gene body hypomethylation of pyroptosis-related genes NLRP7, NLRP2, and NLRP3 facilitate non-invasive surveillance of hepatocellular carcinoma.焦亡相关基因 NLRP7、NLRP2 和 NLRP3 的基因本体低甲基化有助于肝细胞癌的非侵入性监测。
Funct Integr Genomics. 2023 Jun 5;23(2):198. doi: 10.1007/s10142-023-01114-z.
6
Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors.用于胃肠道肿瘤无创成像的靶向CLDN18.2免疫正电子发射断层显像探针的研发
J Pharm Anal. 2023 Apr;13(4):367-375. doi: 10.1016/j.jpha.2023.02.011. Epub 2023 Feb 28.

本文引用的文献

1
Cancer incidence and mortality in China, 2015.2015年中国的癌症发病率和死亡率
J Natl Cancer Cent. 2020 Dec 17;1(1):2-11. doi: 10.1016/j.jncc.2020.12.001. eCollection 2021 Mar.
2
Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.新型抗 HER2 治疗性抗体 RC48 治疗人表皮生长因子受体 2 过表达的局部晚期或转移性胃或胃食管结合部腺癌患者的有效性和安全性：一项单臂、Ⅱ期研究。
Cancer Commun (Lond). 2021 Nov;41(11):1173-1182. doi: 10.1002/cac2.12214. Epub 2021 Oct 19.
3
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma.FAST：一项关于zolbetuximab（IMAB362）联合EOX 对比 EOX 一线治疗晚期 CLDN18.2 阳性胃和胃食管腺癌的随机 II 期研究。
Ann Oncol. 2021 May;32(5):609-619. doi: 10.1016/j.annonc.2021.02.005. Epub 2021 Feb 19.
4
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.